The UCLA MedTech Partnering Conference would not be possible if it was not for the generous support of our sponsors and event partners. We are extremely grateful for their help in making the event possible!
Please join us in thanking the following organizations (click the logo to learn more about each contributor) for their contributions and commitment to furthering innovation.
The California NanoSystems Institute (CNSI) at UCLA produces life-changing scientific, economic and social impact in California and across the world. The CNSI environment fosters interdisciplinary teams that collaborate on high-impact research, leveraging the Institute’s leading-edge facilities and expert services to address grand challenges of our time. Our team supports innovative startups with progressive training and infrastructure to drive commercialization of research-based technologies. We provide unique educational opportunities for the modern scientific leader by engaging learners from primary school students to established scientists and industry professionals.
The UCLA Clinical and Translational Science Institute (CTSI) is a research partnership of UCLA, Cedars-Sinai Medical Center, Charles R. Drew University of Medicine and Science and the Los Angeles Biomedical Institute at Harbor UCLA Medical Center. Its mission is to bring biomedical innovations to bear on the greatest health needs of Los Angeles—the largest and one of the most ethnically, socially and economically diverse counties in the United States. Its vision is to catalyze research that translates discoveries into tangible improvements in health care, disease prevention and treatment in Los Angeles County.
The UCLA CTSI is one of more than 60 research “hubs” supported by the Clinical and Translational Sciences Award (CTSA) program National Center for Advancing Translational Sciences (NCATS).
Murgitroyd is a global firm of European patent attorneys and trade mark attorneys, with offices across Europe and the US. As one of the world’s leading intellectual property attorney firms, we understand inventiveness because it’s what drives our business. So when it comes to supporting innovation, we’re speaking your language.
Option3, a privately held medical device incubator formed in 2010 by James Dreher and Research Corporation Technologies (RCT), focuses on fast-to-market, proprietary technologies.
Option3’s highly experienced team and hands on approach creates an extremely lean, efficient and innovative environment in which cutting-edge technologies are developed and rapidly commercialized.
Our relationship with RCT, an evergreen fund, allows us to create a unique vehicle for each portfolio company that facilitates partnering and provides alternative liquidity opportunities not currently available in the typical venture backed start-up.
PMI is a preclinical contract research organization (CRO) specializing in medical device testing. The organization’s focus is to guide research and development teams to move from initial exploration trials into clinical application as effectively and efficiently as possible. As a CRO, the main priority is to identify and target a client’s long term goals while assisting in the process. This proactive approach ensures that client research is done as accurately as possible the first time.
Riverside Law is founded on the principle that the practice of law and resolution of complex legal issues is best achieved through a true partnership with the client. The attorneys and agents at Riverside came together to form this new enterprise because of their genuine interest in their clients’ business. Even more importantly, these individuals each possess a passion for the process of integrating law and science as a means for successfully advancing their clients’ business objective for their proprietary technologies.
Quallion designs, fabricates and manufactures state-of-the-art lithium ion cells and battery packs, and develops new battery chemistries for the military, aerospace, medical and automotive industries. Building on its legacy leadership position in the medical device industry, the company has developed a range of novel enabling technologies that include the world’s smallest implantable secondary battery and the proprietary Zero-Volt™ and SaFE-LYTE™ technologies.
Stryker is one of the world’s leading medical technology companies and, together with our customers, is driven to make healthcare better. We offer innovative products and services in Orthopaedics, Medical and Surgical, and Neurotechnology and Spine that help improve patient and hospital outcomes.